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Introduction
There is a strong and direct relationship 
between high blood pressure (BP) and cardio-
vascular disease (CVD) mortality (Lewington 
et al. 2002). High BP remains prevalent in 
the United States and internationally among 
adults over the age of 35 years (Chobanian 
et al. 2003; Frohlich 1997). Rapid increases 
in the prevalence of high BP in low-income 
countries (Gupta and Gupta 2009; Ibrahim 
and Damasceno 2012; Lawes et al. 2003; 
Redon et al. 2011) has likely contributed to 
the rising epidemic of CVD in these popula-
tions (Ibrahim and Damasceno 2012). In 
recent decades, there has been growing aware-
ness of the potential importance of environ-
mental factors such as mercury (Houston 
2011), lead (Navas-Acien et al. 2007), 
cadmium (Eum et al. 2008), and arsenic 
(Abhyankar et al. 2012) in the development 
of high BP. The identification and mitiga-
tion of environmental exposures associated 
with high BP may help reduce CVD risk 
(Abhyankar et al. 2012).
Previous studies have indicated associa-
tions between exposure to inorganic arsenic 
and the development of vascular diseases, 
including high BP, peripheral vascular diseases, 
and ischemic heart disease (Abhyankar et al. 
2012; Chen CJ et al. 1996; Chen Y et al. 
2007a; Tseng et al. 1996). A systematic 
review examining 11 cross-sectional studies 
on arsenic exposure and the prevalence of 
high BP (Abhyankar et al. 2012) found 
that 10 of the 11 studies reported a positive 
association, whereas only one study indicated 
no association. The review included 8 studies 
with arsenic levels of moderate to high (average 
≥ 50 μg/L), and 3 studies with relatively low 
arsenic levels (average < 50 μg/L). However, 
prospective cohort studies that can better 
charac terize the association between arsenic 
and high BP are lacking. Longitudinal studies 
with repeated measurements of BP, which 
provide a powerful tool to evaluate health 
outcomes that change over time, are needed 
to assess whether arsenic is associated with 
increasing BP over time.
It is estimated that millions of Americans 
are exposed to drinking water with arsenic 
concentrations exceeding the World Health 
Organization (WHO) standard (10 μg/L) 
(U.S. Environmental Protection Agency 
2000). In Bangladesh, where the majority 
of the population relies on ground water and 
arsenic contamination of wells is widespread, 
> 50 million people have been chronically 
exposed (British Geological Survey 2007). 
In 2000, we established the Health Effects 
of Arsenic Longitudinal Study (HEALS), a 
large prospective cohort study of 11,746 indi-
viduals in Araihazar, Bangladesh, to assess the 
health effects of arsenic exposure. In cross-
sectional analyses using participants’ baseline 
data, we previously reported a positive asso-
ciation between baseline arsenic exposure, 
measured either in urine or drinking water 
samples, and BP (Chen Y et al. 2007a). To 
charac terize the rate of BP changes related 
to arsenic exposure, we assessed the associa-
tion of baseline arsenic exposure (measured 
both in water and urine) with longitudinal 
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Background: Cross-sectional studies have shown associations between arsenic exposure and 
 prevalence of high blood pressure; however, studies examining the relationship of arsenic exposure 
with longitudinal changes in blood pressure are lacking.
Method: We evaluated associations of arsenic exposure in relation to longitudinal change in blood 
pressure in 10,853 participants in the Health Effects of Arsenic Longitudinal Study (HEALS). 
Arsenic was measured in well water and in urine samples at baseline and in urine samples every 
2 years after baseline. Mixed-effect models were used to estimate the association of baseline well 
and urinary creatinine-adjusted arsenic with annual change in blood pressure during follow-up 
(median, 6.7 years).
result: In the HEALS population, the median water arsenic concentration at baseline was 62 μg/L. 
Individuals in the highest quartile of baseline water arsenic or urinary creatinine-adjusted arsenic 
had a greater annual increase in systolic blood pressure compared with those in the reference 
group (β = 0.48 mmHg/year; 95% CI: 0.35, 0.61, and β = 0.43 mmHg/year; 95% CI: 0.29, 0.56 
for water arsenic and urinary creatinine-adjusted arsenic, respectively) in fully adjusted models. 
Likewise, individuals in the highest quartile of baseline arsenic exposure had a greater annual 
increase in diastolic blood pressure for water arsenic and urinary creatinine-adjusted arsenic, 
(β = 0.39 mmHg/year; 95% CI: 0.30, 0.49, and β = 0.45 mmHg/year; 95% CI: 0.36, 0.55, 
respectively) compared with those in the lowest quartile. 
conclusion: Our findings suggest that long-term arsenic exposure may accelerate age-related 
increases in blood pressure. These findings may help explain associations between arsenic exposure 
and cardiovascular disease.
citation: Jiang J, Liu M, Parvez F, Wang B, Wu F, Eunus M, Bangalore S, Newman JD, 
Ahmed A, Islam T, Rakibuz-Zaman M, Hasan R, Sarwar G, Levy D, Slavkovich V, Argos M, 
Scannell Bryan M, Farzan SF, Hayes RB, Graziano JH, Ahsan H, Chen Y. 2015. Association 
between arsenic exposure from drinking water and longitudinal change in blood pressure 
among HEALS cohort participants. Environ Health Perspect 123:806–812; http://dx.doi.
org/10.1289/ehp.1409004
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changes in BP among 10,853 participants 
in Bangladesh who had well water arsenic 
concentrations ranging from 0.1 to 864 μg/L 
(median = 62 μg/L). 
Materials and Methods
Study population. HEALS is an ongoing 
prospective cohort study in Araihazar, 
Bangladesh. The principle aim of HEALS 
is to investigate the health effects of arsenic 
in drinking water. A detailed description 
of the cohort has been presented elsewhere 
(Ahsan et al. 2006). Briefly, before recruit-
ment, water samples were collected for a set 
of 5,966 continuous wells in a well-defined 
geographic area of 25 km2 in Araihazar. 
Between October 2000 and May 2002, 
11,746 men and women 18–75 years of age 
were recruited who met the following criteria: 
a) married male or female (to reduce loss to 
follow-up), b) resident of the study area for at 
least 5 years, and c) primarily used drinking 
water from 1 of the 5,966 study wells for at 
least 3 years (Ahsan et al. 2006), leading to 
a response rate of 97.5% (original cohort). 
HEALS was expanded to include an additional 
8,287 participants in 2007–2008 (expansion 
cohort) following the same methodologies 
(Wu et al. 2011). The present study focused 
on the original cohort because these indi-
viduals were followed for a longer period of 
time (median, 6.7 years; range, 0.9–8.3 years). 
Baseline interviews were conducted to gather 
information regarding history of well water 
use, demographics, and lifestyle characteristics. 
The cohort is being actively followed, with 
follow-up assessments conducted roughly every 
2 years. The current analysis included data 
from the first (September 2002–May 2004), 
second (September 2004–May 2006), and 
third (June 2007–March 2009) follow-ups, at 
which time a physical examination, collection 
of urine samples, and a structured interview 
were conducted using the same procedures as 
those used in the baseline interview. Informed 
consent was obtained from study participants, 
and study procedures were approved by the 
ethics committee of the Bangladesh Medical 
Research Council and the institutional review 
boards of Columbia University and the 
University of Chicago.
For the present study, we excluded indi-
viduals who died before the first follow-up 
(n = 107), those taking hypertension treat-
ment at baseline (n = 126), those without 
systolic BP (SBP) or diastolic BP (DBP) 
measurements at baseline (n = 380), and indi-
viduals for whom no measurements of SBP 
or DBP were recorded during the follow-up 
(n = 406). The final study population was 
10,853. The distributions of demo graphic 
and lifestyle factors between the overall popu-
lation and the study population were very 
similar (see Supplemental Material, Table S1).
Measurements of arsenic exposure. In 
rural Bangladesh, the majority of the popu-
lation uses a single hand-pumped tube well 
for their primary source of drinking water. 
There is no municipal water treatment. Water 
samples from 5,966 tube wells were collected 
in 50-mL acid-washed bottles after pumping 
each well for 5 min. Samples were immedi-
ately acidified using 1% HCl until December 
2003, after which samples were acidified at 
Columbia University, normally several months 
after collection, because delayed acidification 
does not affect measurement results (van Geen 
et al. 2007). Total arsenic concentration was 
first determined by graphite furnace atomic 
absorption spectrometry (GFAA), with a 
detection limit of 5 μg/L. If water samples 
were found to have arsenic concentrations at 
or below the detection limit of GFAA, they 
were then analyzed by high-resolution induc-
tively coupled plasma mass spectrometry (HR 
ICPMS), with a detection limit of < 0.1 μg/L 
(Chen Y et al. 2007b). The long-term repro-
ducibility determined from consistency stan-
dards included with each run is relatively stable 
over time (Cheng et al. 2004, 2005; van Geen 
et al. 2005).
Spot urine samples were collected in 
50-mL acid-washed tubes from 95.6, 94.5, 
91.6, and 89.9% of the cohort participants 
at baseline and at the first, second, and third 
follow-up visits, respectively. Total arsenic 
concentration was measured by GFAA spec-
trometry using a PerkinElmer (Waltham, 
MA) AAnalyst 600 graphite furnace system 
with a detection limit of 2 μg/L, as previ-
ously described (Nixon et al. 1991). Urinary 
creatinine was analyzed using a method 
based on the Jaffe reaction for adjustment 
of urinary total arsenic concentration (Slot 
1965). The median of creatinine concen-
tration at baseline was 52.3 mg/dL (range, 
2.8–376.0) for men and 41.5 mg/dL (range, 
1.3–303.1) for women.
Given that drinking water was the main 
source of arsenic exposure in the popula-
tion (see Supplemental Material, “Details 
on arsenic exposure in the population”) and 
urinary creatinine-adjusted arsenic can reflect 
internal dose of exposure (Marchiset-Ferlay 
et al. 2012), we used both as indicators for 
arsenic exposure. At baseline, in order to help 
improve the health of the community and 
reduce their risks from arsenic exposure, an 
arsenic mitigation program was implemented 
to promote switching to wells with relatively 
lower water arsenic concentration (< 50 μg/L) 
(Chen Y et al. 2007b). At the first follow-up, 
a total of 58% of the 6,512 participants who 
consumed well water with arsenic concentra-
tions ≥ 50 μg/L at baseline had switched to 
nearby wells. However, among those indi-
viduals that switched wells, only 27% partici-
pants had switched to wells with lower arsenic 
concentrations (i.e., < 50 μg/L) (Chen Y 
et al. 2007b). We used urinary creatinine-
adjusted arsenic assessed at follow-up visits to 
track the change in exposure during follow-
ups (Marchiset-Ferlay et al. 2012). Because 
arsenic level remained similar in the majority 
of the participants (see Supplemental Material, 
“Details of arsenic exposure in the popula-
tion”), the impact of visit-to-visit change of 
urinary creatinine-adjusted arsenic on BP 
change was considered short-term compared 
with urinary creatinine-adjusted arsenic at 
baseline, which reflected exposure from the 
baseline wells that participants had used for an 
average of 8.6 (median, 7; range, 3–50) years 
prior to baseline (Chen Y et al. 2010, 2011, 
2013a, 2013b), and thus visit-to-visit change 
of urinary creatinine-adjusted arsenic was not 
considered as the main exposure of interest.
BP measurements. BP was measured 
at baseline and at each follow-up by trained 
clinicians using an automatic sphygmoma-
nometer (HEM 712-C; Omron Healthcare 
GmbH, Hamburg, Germany), which has 
been validated to have 85% of readings falling 
within 10 mmHg (O’Brien et al. 2001). 
Measurements were taken with participants in 
a seated position after 5 min of rest, with the 
cuff around the upper left arm, in accordance 
with recommended guidelines (Pickering et al. 
2005). Two BP measurements were taken at 
follow-ups, and we used the arithmetic mean 
of two for the analyses. The reliability of the 
BP measurement was high, with all intra class 
correlation coefficients between 0.92 and 0.94 
at a given visit (Chen Y et al. 2007a).
The participation rate for the first, second, 
and third follow-ups, respectively, were 96.9, 
93.6, and 92.2% of the cohort participants at 
baseline. Information on medication use was 
collected at baseline and during follow-ups. 
Study participants were asked about all medi-
cines they were taking regularly, and were 
asked to show the medications or prescrip-
tions to the interviewers. Medications were 
standardized to generic names and then 
sorted into one of 44 medication categories 
(Scannell et al. 2013). Participants who 
reported taking anti hypertensive medication 
were identified for the present study.
Lifestyle characteristics. Lifestyle charac-
teris tics were measured at baseline and follow-
ups, or only at baseline. Past or current use 
of cigarette smoking was ascertained in the 
questionnaire at each follow-up. Diabetes 
status was identified by asking participants 
if they were diagnosed with diabetes by a 
physician. Previously reported comparisons 
between self-reported diabetes status in our 
study and test results for glycosylated hemo-
globin and glucosuria showed that only 1% of 
the individuals without self-reported diabetes 
tested positive on urinary glucose, whereas 
61% of the individuals with self-reported 
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808 volume 123 | number 8 | August 2015 • Environmental Health Perspectives
diabetes tested positive (p < 0.01), which indi-
cated good questionnaire validity (Chen Y 
et al. 2010, 2011). Body mass index (BMI) 
was calculated based on measured height 
and weight (kilograms per meter squared). 
Educational status was obtained at baseline at 
each follow-up.
Statistical analysis. We first conducted 
descriptive analyses to compare the distribution 
of demographic and life style charac teristics and 
BP measurements over time by baseline water 
arsenic categorized into quartiles in the overall 
study population.
We used longitudinal mixed-effect models 
with a random slope and an intercept for 
each subject, to assess the association between 
baseline arsenic, using either water or urinary 
creatinine-adjusted arsenic, and annual 
change in BP over time. The constructed 
mixed-effects model is a two-level model, in 
which the first level describes how BP changes 
in the population (fixed effect), while the 
second level of the model depicts how indi-
vidual BP changes over time (random effect). 
The mixed-effect model also accounts for 
within-subject correlation between baseline 
and follow-up BP measurements.
We first used the mixed-effect model to 
assess the association of baseline demographic 
and life style variables with annual BP change. 
The variables included baseline age (treated 
as continuous or tertile variables), sex (male, 
female), smoking status (never, past, current), 
history of diabetes (yes, no), baseline educa-
tional attainment in years (continuous or 
tertile variables), and BMI (kg/m2).
In order to investigate whether there was 
a dose–response relationship between long-
term exposure to arsenic (either baseline 
water arsenic or baseline urinary creatinine-
adjusted arsenic) and longitudinal BP change, 
arsenic concentrations were categorized into 
quartiles, and the mixed-effect model was also 
conducted as follows:
BPij = [β0 + β1 (TIME)ij + β2 As0j2  
 + β3 As0j3 + β4 As0j4  
 + β12 As0j2 (TIME)ij  
 + β13 As0j3 (TIME)ij  
 + β14 As0j4 (TIME)ij + αTZ0j]  
 + [μ0j + μ1j (TIME)ij] + rij,  [1]
where baseline arsenic exposure (either water 
arsenic or urinary creatinine-adjusted arsenic) 
was categorized into quartiles and treated 
with a dummy variable (As0j2, As0j3, As0j4). 
BPij represents blood pressure at time i for 
subject j. TIME is years since baseline at the 
time of BP measurement; βk, k = 2,3,4 is the 
difference in mean baseline BP for baseline 
arsenic in the kth quartile compared with that 
in the first quartile (reference); β1k, k = 2,3,4 
is the difference in annual BP change over 
time for baseline arsenic in the kth quartile 
compared with the reference (i.e., the esti-
mated effect of baseline arsenic levels on 
annual BP change); αT is a row vector of 
regression coefficient estimates for covariates 
at baseline (T denotes vector transpose); and 
Z0j is a vector of potential confounders. The 
random intercept μ0j and slope μ1j estimate 
the within-subject correlation among repeated 
measurements and between-subject hetero-
geneity, and rij is the error that cannot be 
accounted for by other covariates and random 
effects. The terms in the first and second 
brackets, respectively, are the fixed and 
random parts of the model. An unstructured 
variance structure was specified that assumes 
that there was no specific pattern in the cova-
riance matrix. BP was normally distributed 
at baseline and follow-ups, and was therefore 
not transformed. To assess the association 
between baseline water arsenic and annual 
BP change, we first adjusted for sex and age 
(years) (model 1). We then additionally 
adjusted for BMI (time dependent), smoking 
status (time dependent, categorized into 
current or not current), history of diabetes 
(time dependent), and educational attainment 
(model 2) because these variables were consid-
ered important risk factors for high BP in our 
population (Chen Y et al. 2007a). Because 
arsenic exposures may have changed from 
baseline levels in some participants, in the 
final model (model 3) we further adjusted for 
change in urinary creatinine-adjusted arsenic 
since baseline for each visit, calculated as the 
arsenic concentration at each follow-up minus 
arsenic concentration in the baseline. Similar 
models were constructed using baseline 
urinary creatinine-adjusted arsenic as the 
exposure variable. We also examined differ-
ences in rate of BP change associated with 
visit-to-visit changes in urinary creatinine-
adjusted arsenic.
In all analyses, BP measurements were 
treated as missing for the visit when the use 
of anti hypertension treatment was reported 
and thereafter. There were 126 participants 
being treated with anti hypertension medica-
tion at baseline, 285 at the first follow-up, 
412 at the second follow-up, and 658 at 
the third follow-up. We also conducted the 
same analyses using different categories of 
arsenic exposure (tertiles or quintiles). We 
conducted sensitivity analyses excluding all 
subjects who were ever under treatment at 
baseline or at any follow-up visits. We used 
the same equipment and protocol to measure 
BP at baseline and at every follow-up visit. 
However, because BP measurements in the 
second follow-up appeared to be elevated 
compared with BP measurements at other 
time points, we did a sensitivity analysis to 
exclude BP measurements in that follow-up.
Finally, we examined whether subjects 
with higher baseline arsenic exposure (water 
arsenic or urinary creatinine-adjusted arsenic) 
had higher BP at the end of follow-up. Linear 
regression models were used, with the arsenic 
exposure variables treated as categorical 
variables, adjusting for the same covariates. 
Adjusted mean levels of BP by quartiles of 
arsenic exposure variables were estimated 
using LSMEANS statement in SAS. All 
statistical analyses were conducted using SAS, 
version 9.3 (SAS Institute Inc., Cary, NC, 
USA). All tests conducted were two-sided, 
and p < 0.05 was considered significant.
Results
The final study population included 10,853 
participants, with median follow-up time of 
6.7 years, ranging from 0.86 to 8.26 years. 
The median concentration was 62 μg/L 
for water arsenic and 88 μg/L for urinary 
arsenic, ranging from 0.1 to 864 μg/L and 
1 to 2,273 μg/L, respectively. Of the study 
population, 9,070 had all four SBP measure-
ments and 9,062 had all four DBP measure-
ments; 1,150 had three SBP measurements 
and 1,159 had three DBP measurements; and 
633 had two SBP measurements and 632 had 
two DBP measurements. There were 10,853 
subjects with available water arsenic concen-
trations and 10,549 subjects with available 
baseline urinary creatinine-adjusted arsenic 
concentrations for analysis.
Individuals with lower baseline arsenic 
exposure were slightly more likely to have 
higher educational attainment or higher 
baseline BMI (Table 1). There was no 
significant difference in SBP or DBP by 
water arsenic tertile groups at baseline, first 
follow-up, or second follow-up. However, 
there were global differences in SBP and 
DBP measured at the third visit in relation 
to baseline water arsenic levels. Baseline water 
arsenic levels were positively associated with 
urinary creatinine-adjusted arsenic levels at 
baseline, first follow-up, second follow-up, 
and third follow-up.
The rate of annual SBP increase tended 
to be greater with increasing baseline age 
(Table 2). Age was inversely associated with 
the rate of longitudinal DBP increase. There 
was a monotonic decrease with increasing 
age, comparing older age groups (30–40, 
> 40 years of age) with younger age group 
(≤ 30 years of age), and the difference 
between the rate of DBP decrease among 
those > 40 years at baseline was close to 
being significantly lower than the rate among 
those ≤ 30 years at baseline. The data are 
consistent with previous literature that docu-
mented a decreasing DBP with increasing 
age (Wright et al. 2011). The annual increase 
in SBP was greater in women compared 
with men, in those with higher educational 
attainment than subjects with a lower 
educational attainment, and in those with a 
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baseline BMI > 20.45 kg/m2 compared with 
18.09–20.45 kg/m2.
Tables 3 and 4 show the associations 
of arsenic exposure categorized into quar-
tiles and annual change in SBP or DBP. 
For SBP, we observed a positive associa-
tion without a dose–response relationship 
throughout three models; individuals in 
the higher three quartiles of baseline water 
arsenic or urinary creatinine-adjusted 
arsenic had a greater annual increase in 
SBP compared with those in the refer-
ence group (β = 0.43–0.54 mmHg/year 
and β = 0.39–0.44 mmHg/year for water 
arsenic and urinary creatinine-adjusted 
arsenic, respectively) in fully adjusted models 
(Table 3). Likewise, for DBP, a positive rela-
tionship was also observed; individuals in 
the higher three quartiles of baseline arsenic 
exposure had a greater annual increase in 
DBP (β = 0.39–0.41 mmHg/year, and 
β = 0.37–0.45 mmHg/year for water arsenic 
and urinary creatinine-adjusted arsenic, 
respectively) in fully adjusted models 
compared with those in the lowest quartile 
(Table 4). For DBP there was a monotonic 
increase in the rate with increasing urinary 
creatinine-adjusted arsenic (Table 4). Analyses 
using different categories of arsenic exposure 
(tertiles or quintiles) showed similar results 
(see Supplemental Material, Tables S2 
and S3). Sensitivity analyses were conducted 
by excluding all subjects who were under 
treatment for hypertension at baseline or 
follow-up (n = 545), without change in the 
overall results (data not shown). In an analysis 
of associations with changes in creatinine-
adjusted urinary arsenic over time, with 
the least amount of change between visits 
(creatinine-adjusted urinary arsenic at later 
visit minus creatinine-adjusted urinary arsenic 
at earlier visit) as the reference group (ranging 
from a decrease of 9 to an increase of 39 μg/g 
creatinine), the greatest increase (> 39 μg/g 
creatinine) had a positive but non significant 
association with the mean annual increase in 
SBP [β = 0.40; 95% confidence interval (CI): 
–0.04, 0.83] and DBP (β = 0.28; 95% CI: 
–0.03, 0.59), whereas there was no associa-
tion with a decrease of > 9 μg/g creatinine 
over follow-up (data not shown). Because 
mean SBP and DBP both were highest at the 
second follow-up visit (suggesting a possible 
systematic error in measurement), we repeated 
Table 1. Baseline and follow-up characteristics of HEALS participants (N = 10,853).
Characteristic
Q1 (≤ 12 μg/L) Q2 (12–62 μg/L) Q3 (62–148 μg/L) Q4 (> 148 μg/L)
p-ValueaNo. Mean ± SD or % No. Mean ± SD or % No. Mean ± SD or % No. Mean ± SD or %
Age (years) 2,752 36.9 ± 10.0 2,711 36.6 ± 10.0 2,688 36.6 ± 9.9 2,702 37.0 ± 10.0 0.234
Male (%) 1,170 42.5 1,143 42.2 1,124 41.8 1,151 42.6 0.935
Current smoker (%) 813 29.6 792 29.2 747 27.8 751 27.8 0.334
Diabetes history (%) 55 2.0 59 2.2 46 1.7 43 1.6 0.370
Education (years) 2,750 3.6 ± 3.9 2,710 3.2 ± 3.7 2,687 3.5 ± 3.9 2,700 3.3 ± 3.7 0.002
BMI baseline (kg/m2) 2,730 19.9 ± 3.3 2,701 19.7 ± 3.1 2,670 19.7 ± 3.0 2,690 19.4 ± 3.0 < 0.001
Systolic blood pressure (mmHg)
Baseline 2,752 113.6 ± 16.6 2,711 114.7 ± 17.2 2,688 113.6 ± 16.5 2,702 113.5 ± 16.6 0.391
Follow up 1 2,676 113.9 ± 16.8 2,639 113.7 ± 17.0 2,623 113.5 ± 17.1 2,639 114.2 ± 17.4 0.442
Follow up 2 2,557 118.4 ± 15.6 2,475 117.8 ± 15.3 2,492 117.8 ± 15.5 2,489 117.4 ± 15.2 0.175
Follow up 3 2,432 108.5 ± 14.9 2,399 112.6 ± 14.8 2,366 112.6 ± 15.7 2,356 112.0 ± 15.6 < 0.001
Diastolic blood pressure (mmHg)
Baseline 2,750 73.8 ± 11.5 2,711 73.6 ± 11.3 2,685 73.4 ± 11.1 2,700 73.1 ± 11.5 0.132
Follow up 1 2,677 73.0 ± 10.2 2,638 72.8 ± 10.3 2,623 72.6 ± 10.2 2,639 72.9 ± 10.3 0.557
Follow up 2 2,557 76.3 ± 10.3 2,475 76.2 ± 10.0 2,492 76.1 ± 10.0 2,489 76.0 ± 10.1 0.683
Follow up 3 2,432 71.1 ± 9.9 2,399 73.9 ± 10.0 2,366 73.8 ± 10.2 2,356 73.4 ± 10.1 < 0.001
Urinary arsenic (μg/L)
Baseline 2,711 51.0 ± 47.7 2,662 99.2 ± 79.3 2,576 150.9 ± 120.4 2,600 258.2 ± 233.8 < 0.001
Follow up 1 2,671 54.3 ± 57.7 2,633 106.9 ± 87.5 2,625 145.3 ± 133.8 2,629 185.7 ± 199.1 < 0.001
Follow up 2 2,621 54.7 ± 55.6 2,534 105.7 ± 85.5 2,547 139.1 ± 125.6 2,542 178.5 ± 191.4 < 0.001
Follow up 3 2,564 51.6 ± 57.5 2,510 92.8 ± 77.7 2,499 118.6 ± 108.8 2,484 149.2 ± 169.5 < 0.001
Urinary creatinine-adjusted arsenic (μg/g creatinine) 
Baseline 2,711 99.8 ± 83.5 2,662 209.1 ± 151.7 2,576 316.8 ± 200.5 2,600 525.8 ± 488.1 < 0.001
Follow up 1 2,671 96.7 ± 74.4 2,633 193.1 ± 121.8 2,625 264.2 ± 213.6 2,629 344.9 ± 326.7 < 0.001
Follow up 2 2,621 98.5 ± 79.4 2,534 198.0 ± 120.6 2,547 259.2 ± 201.1 2,542 333.1 ± 323.1 < 0.001
Follow up 3 2,564 99.0 ± 89.5 2,510 190.2 ± 153.6 2,499 247.8 ± 191.2 2,484 305.1 ± 309.7 < 0.001
Abbreviations: Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4. Q1: median = 2.3, SD = 3.3, range = 11.9; Q2: median = 34.0, SD = 14.4, range = 49.7; Q3: median = 101.0, SD = 25.2, 
range = 86.0; Q4: median = 239.0, SD = 107.4, range = 714.0.
aRepresents the global difference and is based on the chi-square test for categorical variables and analysis of variance for continuous variables.
Table 2. Relation of baseline characteristics and adjusted annual changes in blood pressure over 7 years 
of follow-up.a
Baseline characteristic
SBP change/year (mmHg)  
β (95% CI) p-Value
DBP change/year (mmHg)  
β (95% CI) p-Value
Age (years)b
≤ 30 Reference Reference
30–40 0.14 (0.02, 0.27) 0.020 –0.05 (–0.14, 0.03) 0.201
> 40 0.36 (0.23, 0.49) < 0.001 –0.09 (–0.18, 0.01) 0.064
Sex (women compared with 
men)
0.34 (0.20, 0.48) < 0.001 0.01 (–0.10, 0.10) 0.950
Smoking statusb
Never Reference Reference
Past –0.01 (–0.23, 0.22) 0.939 –0.05 (–0.21, 0.10) 0.529
Current 0.11 (–0.05, 0.26) 0.179 0.08 (–0.03, 0.19) 0.168
Diabetes history –0.19 (–0.53, 0.14) 0.257 –0.22 (–0.46, 0.01) 0.060
Education length (years)b
0 Reference Reference
0–5 0.18 (0.06, 0.29) 0.003 0.06 (–0.02, 0.14) 0.135
> 5 0.28 (0.16, 0.41) < 0.001 0.02 (–0.07, 0.10) 0.669
BMI baseline (kg/m2)b
≤ 18.09 –0.03 (–0.15, 0.10) 0.660 0.07 (–0.01, 0.16) 0.089
18.09–20.45 Reference Reference
> 20.45 0.19 (0.06, 0.31) 0.003 –0.07 (–0.16, 0.01) 0.09
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index.
aWhen one variable was put in the model, all other variables were adjusted in the same model. bCategorized by tertiles. 
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analyses excluding follow-up 2 data but found 
similar results to analyses including data from 
all visits (data not shown).
Last, we assessed the association between 
baseline arsenic exposure and the absolute 
levels of BP at the third follow-up (see 
Supplemental Material, Figure S1). In fully 
adjusted models, individuals with the highest 
level of baseline water arsenic had 3.95 mmHg 
(95% CI: 3.15, 4.76) greater SBP or 2.65 
mmHg (95% CI: 2.21, 3.31) greater DBP 
compared with those in the reference group. 
Similarly, for urinary creatinine-adjusted 
arsenic, individuals with higher concentra-
tions had a 3.47 mmHg (95% CI: 2.61, 4.33) 
increase in SBP or a 2.62 mmHg (95% CI: 
1.95, 3.03) increase in DBP compared with 
those in the lowest quartile. However, associa-
tions were similar across quartiles 2, 3, and 4, 
without evidence of a monotonic trend (see 
Supplemental Material, Figure S1).
Discussion
To our knowledge, the present study is the 
first large epidemiologic study to examine 
the relationship between arsenic exposure 
from drinking water and longitudinal change 
in BP. We found positive associations of 
arsenic exposure, measured either in well 
water or urine samples, with annual change 
in SBP and DBP, over an average of 6.7 years 
of follow-up.
The association of arsenic exposure 
with BP has been indicated in several cross-
sectional studies. A systematic review including 
11 cross-sectional studies reported a pooled 
OR of 1.27 (95% CI: 1.09, 1.47; p-value for 
heterogeneity = 0.001) for high BP comparing 
the highest and lowest arsenic exposure 
categories (Abhyankar et al. 2012). However, 
cross-sectional assessments of the association 
between arsenic exposure and BP are limited 
by a) possible selection bias in capturing only 
individuals who have lived long enough, and 
b) limited detection of the latent effects of 
arsenic exposure on BP. In contrast, longitu-
dinal analyses mitigate some of these problems 
and may be a superior method for examining 
arsenic exposure on BP change over time. 
Longitudinal analyses have previously revealed 
the effects of lead exposure on BP change 
(Glenn et al. 2003, 2006). Our findings 
demonstrating an association between arsenic 
exposure and annual BP change contributes to 
the growing body of evidence indicating that 
environmental exposures may play a role in 
longitudinal BP change.
We did not find a monotonic relation-
ship between arsenic exposure and the slope 
of BP change over time. In our previous 
cross-sectional study, the positive associa-
tion between arsenic exposure from drinking 
water and baseline BP also was not stronger 
with increasing quartiles of arsenic exposure 
(Chen Y et al. 2007a). Mechanistic studies 
have indicated that the vascular effect of arsenic 
may be non linear (Soucy et al. 2003) and may 
reach threshold when arsenic exposure exceeds 
a certain level. Alternatively, the baseline BP 
may have been affected by arsenic exposure 
already leading to a limited increase on the rate 
of BP change that can be further observed. In 
addition, the increased rate of BP change may 
be limited in this relatively young cohort.
In the present study, exposure to water 
with arsenic concentrations > 12 μg/L was 
associated with a greater increase of 0.43–
0.54 mmHg/year and 0.39–0.41 mmHg/year 
for SBP and DBP, respectively. Evidence 
suggests that the risk of CVD rises continu-
ously as both SBP and DBP increase from 
115 mmHg and 75 mmHg, respectively 
(Lewington et al. 2002). Based on estimates 
from 61 prospective observational studies, 
even a 2-mmHg decrease in usual SBP would 
involve about 10% lower stroke mortality 
and about 7% lower mortality from ischemic 
heart disease or other vascular causes in 
middle age (Lewington et al. 2002). Although 
the estimate may not be the same in our 
study population, given the strong association 
between BP and CVD risk, the differences in 
the rate of BP change associated with arsenic 
exposure, although small in magnitude 
annually, may have a cumulative effect on the 
risk of clinical events. 
The potential association between arsenic 
exposure and high BP is supported by experi-
mental studies. In vitro work has shown that 
arsenic promotes inflammatory activity, oxida-
tive stress, and endothelial dysfunction through 
several mechanisms, including the activation 
of stress-response transcription factors such 
as activator protein-1 and nuclear factor-κB 
(Abhyankar et al. 2012). In animal models, 
chronic exposure of rats and rabbits to arsenite 
has been shown to cause a considerable 
increase in peripheral vascular resistance (Abir 
et al. 2012). In rats, lifelong arsenic exposure 
increased BP after only 80 days, and eleva-
tions persisted through 200 days (Yang et al. 
2007). Furthermore, arsenic exposure may also 
be related to renal dysfunction, leading to BP 
changes in individuals (Chen JW et al. 2011; 
Hsueh et al. 2009).
Our study, which is among the first to 
prospectively investigate the role of arsenic 
exposure in longitudinal BP change, has 
several strengths. First, we have obtained 
multiple research-quality BP measurements 
over 7 years of follow-up, which enables us 
to depict BP longitudinal change over time. 
Table 3. Relation of baseline water arsenic (N = 10,853) and baseline urinary creatinine-adjusted arsenic 
(N = 10,549) with adjusted annual changes in systolic blood pressure (SBP) over 7 years of follow-up. 
Baseline exposure Range
Model 1  
change/year (mmHg)
Model 2  
change/year (mmHg)
Model 3  
change/year (mmHg)
Water arsenic (μg/L) 
Q1 < 12 Reference Reference Reference
Q2 12–62 0.45 (0.32, 0.58) 0.42 (0.29, 0.56) 0.43 (0.29, 0.56)
Q3 62–148 0.60 (0.46, 0.73) 0.55 (0.42, 0.68) 0.54 (0.40, 0.67)
Q4 > 148 0.51 (0.38, 0.65) 0.48 (0.34, 0.61) 0.48 (0.35, 0.61)
Urinary creatinine-adjusted arsenic  
(μg/g creatinine) 
Q1 < 106 Reference Reference Reference
Q2 106–199 0.40 (0.26, 0.53) 0.38 (0.25, 0.52) 0.39 (0.25, 0.52)
Q3 199–352 0.45 (0.32, 0.59) 0.43 (0.30, 0.57) 0.44 (0.30, 0.58)
Q4 > 352 0.45 (0.31, 0.58) 0.41 (0.27, 0.54) 0.43 (0.29, 0.56)
Abbreviations: Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4. Model 1: controlled for baseline age and 
sex. Model 2: controlled for model 1 covariates plus BMI, smoking status, educational status, and history of diabetes. 
Model 3: controlled for model 2 covariates plus change of urinary creatinine-adjusted arsenic since baseline.
Table 4. Relation of baseline water arsenic (N = 10,846), baseline urinary creatinine-adjusted arsenic 
(N = 10,549) with adjusted annual changes in diastolic blood pressure (DBP) over 7 years of follow-up. 
Baseline exposure Range
Model 1  
change/year (mmHg)
Model 2  
change/year (mmHg)
Model 3  
change/year (mmHg)
Water arsenic (μg/L) 
Q1 < 12 Reference Reference Reference
Q2 12–62 0.44 (0.35, 0.53) 0.42 (0.33, 0.52) 0.41 (0.31, 0.50)
Q3 62–148 0.47 (0.38, 0.56) 0.42 (0.33, 0.52) 0.41 (0.32, 0.51)
Q4 > 148 0.43 (0.34, 0.52) 0.40 (0.31, 0.49) 0.39 (0.30, 0.49)
Urinary creatinine-adjusted arsenic  
(μg/g creatinine) 
Q1 < 106 Reference Reference Reference
Q2 106–199 0.38 (0.29, 0.48) 0.37 (0.27, 0.46) 0.37 (0.27, 0.46)
Q3 199–352 0.40 (0.30, 0.49) 0.37 (0.27, 0.46) 0.38 (0.28, 0.47)
Q4 > 352 0.49 (0.40, 0.58) 0.45 (0.35, 0.54) 0.45 (0.36, 0.55)
Abbreviations: Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4. Model 1: controlled for baseline age and 
sex. Model 2: controlled for model 1 covariates plus BMI, smoking status, educational status, and history of diabetes. 
Model 3: controlled for model 2 covariates plus change of urinary creatinine-adjusted arsenic since baseline.
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Second, the low percentage of the population 
using anti hypertensive medications (around 
1% at baseline) and the absence of alcohol 
consumption due to religious beliefs allowed 
us to investigate BP change without the influ-
ence of medical therapy or alcohol. Finally, 
we have a rich set of covariates that allow us 
to adjust for confounders.
The study also has limitations. Although 
we used the same methodology for measuring 
BP since baseline and for follow-ups, 
measurement errors for BP measurements 
could have occurred. We could not estimate 
the extent of the potential measurement 
errors. However, the relationships between 
conventional risk factors and longitudinal 
change in BP were consistent with those of 
the literature, supporting the validity of the 
BP measurement in this study. Also, sensi-
tivity analysis excluding follow-up 2, which 
was conducted out of concern for error at 
follow-up 2, generated similar results. The self-
reported well water use might also produce 
misclassifications of exposure. However, the 
correlation of well water arsenic concentra-
tion and urinary creatinine-adjusted arsenic 
at baseline was high (ρ = 0.70), supporting 
the validity of self-reported data on well use 
and population-wide arsenic exposure in this 
population. The analyses were restricted to 
individuals with available data on repeated 
BP measurements. Because arsenic exposure 
has been related to CVD mortality in the 
cohort and high BP is a CVD risk factor, 
the exclusion of individuals without repeated 
BP measurements may have preferentially 
removed individuals with high BP that is 
associated with arsenic, leading to a potential 
bias toward the null on average. However, 
missing BP was not extensive (9,069 subjects 
have complete BP measurements), and the 
demographic distributions of our study popu-
lation and the overall population were very 
similar (see Supplemental Material, Table S1). 
In the analyses, we controlled for visit-to-visit 
changes in urinary creatinine-adjusted arsenic. 
However, given that arsenic exposure was 
similar in the majority of participants, we may 
not have power to assess the effects of changes 
in urinary creatinine-adjusted arsenic. We 
did not assess the role of specific nutrients or 
nutritional intake in the present study. Future 
studies are needed to investigate whether the 
association of arsenic exposure and the rate of 
BP change differs by nutritional status.
Conclusion
We found positive associations between 
long-term arsenic exposure and BP increase 
over time, which might be one mechanism 
by which arsenic may lead to CVD. Further 
studies are needed to investigate other 
pre clinical indicators or biomarkers of CVD 
with multiple measurements.
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